On May 23, Shanghai Junshi Biosciences Co.Ltd(688180) -u ( Shanghai Junshi Biosciences Co.Ltd(688180) , SH) announced that, Its holding subsidiary Shanghai juntuo Biomedical Technology Co., Ltd. (hereinafter referred to as juntuo Biology) and Suzhou Wangshan wangshui biomedical Co., Ltd. (hereinafter referred to as Wangshan wangshui) jointly developed oral nucleoside anti SARS cov-2 drug vv116 tablets (hereinafter referred to as vv116) in a pair of binamatvir tablets / ritonavir tablets (i.e. Pfizer covid-19 oral drug paxlovid) The phase III registered clinical study (nct05341609) for the early treatment of mild to moderate novel coronavirus pneumonia reached the primary endpoint of the protocol.
According to the announcement, Ning Guang, academician of Ruijin Hospital Affiliated to the Medical College of Shanghai Jiaotong University, served as the main investigator of the clinical study, and 822 patients were actually enrolled. The main end point of the study was “the time to continuous clinical recovery”, and the secondary end points included “the percentage of subjects with covid-19 progression (defined as the progression of severe / critical covid-19 or all-cause death) by the 28th day”.
The results of this clinical study showed that vv116 for the early treatment of mild to moderate covid-19 reached the primary endpoint preset by the clinical protocol Shanghai Junshi Biosciences Co.Ltd(688180) said that the company would communicate with the drug regulatory authorities to submit the application for the listing of new drugs in the near future.
